Antibacterial Drugs: World Industry and Market Prospects 2015 2025

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

Antibacterial Drugs: World Industry and Market Prospects

2015-2025

www.visiongain.com

Contents

1. Report Overview

1.1 Overview of Findings

1.2 Why You Should Read This Report

1.3 How This Report Delivers

1.4 Main Questions Answered by This Analysis

1.5 Who is This Study For?

1.6 Research and Analysis Methods

1.7 Frequently Asked Questions (FAQs)

1.8 Some Associated Reports

1.9 About Visiongain

2. Introduction to Antibacterial Drugs 2.1 Types of Bacterial Infection

2.2 Main Bacteria Causing Infections in Human Beings

2.3 Incidence and Mortality Profiles for Common Bacterial Infection

2.4 Treating Infections

2.4.1 The History of Antibacterial Drug Development

2.4.2 Mechanisms of Action

2.4.3 Leading Classes of Antibacterial Medicines

2.4.3.1 Cephalosporins

2.4.3.2 Penicillins

2.4.3.3 Carbapenems

2.4.3.4 Fluoroquinolones

2.4.3.5 Macrolides

2.4.4 Antibacterial Drug Resistance

3. Antibacterial Drugs: World Market, 2015-2025

3.1 Antibacterials’ Revenues Plateau between 2009 and 2013

3.2 Antibacterial Agents - Market Segmentation

3.3 Antibiotics Market Forecast, 2015-2025: Decline in Revenues for Fluoroquinolones

3.4 Drivers and Restraints in the Antibacterials Market, 2015-2025

3.5 Generic Erosion and Prescription Control will Limit Market Growth

3.6 Changes in that Industry Sector’s Market Shares, 2015-2025

3.7 Pfizer is the Leader in the Antibacterial Drugs Market

3.8 Fragmented Market to Fracture Further

4. Cephalosporins Market Forecast, 2015-2025

4.1 Cephalosporins Market 2013-2014 – No Dominant Brands

4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2015 and 2025

4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead Cephalosporin Market Between

2015 and 2025

4.1.3 Drivers and Restraints on the Cephalosporins Market, 2015-2025

4.1.4 Cephalosporins Lack Market Exclusivity

4.1.5 Strong Pipeline for Novel Cephalosporins

4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US

4.1.6.1 Off Patent but Still Effective

4.1.6.2 Declining Revenues Owing to Competition - Forecast 2015-2025

4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs

4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2015-2025

4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin

4.1.8.1 Continued Decline in Revenue - Forecast 2015-2025

www.visiongain.com

4.1.9 Meiact – A Broad Range Community Antibiotic

4.1.9.1 Spectracef Sales in the US Leads to Pass the Product

4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2015-2025

4.1.10 Flomox - Shionogi’s Third-Generation Cephalosporin

4.1.10.1 Patent Issues and Litigation

4.1.10.2 Genericisation and Safety to Restrict Sales - Forecast 2015-2025

4.1.11 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation

Cephalosporins

4.1.11.1 Unmet Needs in Pneumonia to Drive Growth - Revenue Forecast 2015-2025

4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe

4.1.12.1 Future Sales Dictated by US Approval - Revenue Forecast 2015-2025

4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial

4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake - Revenue Forecast

2015-2025

4.1.14 CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015

4.1.14.1 Competition from CXA-201 to Limit Sales - Forecast 2015-2025

5. Penicillins Market Forecast, 2015-2025 5.1 Generics and Augmentin Dominate the Penicillins Market in 2013 and 2014

5.2 Augmentin to Lose its Dominance over the Coming 10 Years - Market Shares for Penicillin

Drugs, 2015-2025

5.3 Penicillin Antibacterials: Market Forecast 2015-2025

5.4 Drivers and Restraints for the Penicillin Market 2015-2025

5.5 Augmentin – Blockbuster Facing Generic Competition

5.5.1 Augmentin – Challenges in Some Countries

5.5.2 Stable Revenues in Spite of Generic Competition

www.visiongain.com

5.5.3 Revenue Forecast 2015-2025

5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) - Pneumonia Therapeutic

5.6.1 Patent Expiry and Revenue Extension for Pfizer

5.6.2 Historic and Current Revenue Performance


5.7 Unasyn – Gram-negative and Positive Antibiotic

5.7.1 Falling Revenues - Forecast 2015-2025

5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand

5.8.1 Marginal Decline in Revenue - Forecast 2015-2025

5.9 Generic Amoxicillin


5.10 Generic Amoxicillin-Clavulanic Acid


6. Fluoroquinolone Market Forecast, 2015-2025

6.1 The Fluoroquinolone Market 2013-2014

6.2 Changing Market Share for Fluoroquinolone Antibacterials, 2015-2025

6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2015-2025

6.4 Trends in the Fluoroquinolone Market

6.4.1 Safety Fears for Fluoroquinolones

6.4.2 Avelox Patent Cliff

6.4.3 Inhaled Fluoroquinolone Formulations

6.5 Fluoroquinolone Market Forecast 2015-2025

6.6 Avelox

6.6.1 Safety Profile Hampers Sales

www.visiongain.com

6.6.2 Generic Competition


6.7 Cravit and Levaquin

6.7.1 Generic Competition Affecting Revenue Worldwide

6.7.2 Lifecycle Management for Cravit and Levaquin


6.8 Vigamox

6.8.1 Branded and Generic Challenges 2010-2013

6.8.2 Moxeza: A Next-Generation Form of Vigamox


6.9 Cirpodex and Cipro – Two Preparations of Ciprofloxacin

6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic

6.9.1.1 Revenue Forecast 2015-2025

6.9.2 Cipro Revenue Forecast 2015-2025: Continued Generic Erosion

6.10 Geninax


6.11 Delafloxacin


7. Macrolide Market Forecast, 2015-2025 7.1 Macrolide Market in 2013-2014

7.2 Changing Market Share for Macrolides, 2015-2025

7.3 Macrolide Antibacterials: Market Forecast 2015-2025

7.4 Trends in the Macrolide Market

7.5 Biaxin/Clarith

www.visiongain.com

7.5.1 Revenue 2013-2014

7.5.2 Lifecycle Management for Continued Market Presence


7.6 Zithromax

7.6.1 Concerns Over Safety and Marketing in the US

7.6.2 Effectiveness in Drug-Resistant Strains


7.7 Dalacin


7.8 Dificid

7.8.1 Rapid Uptake Slowed by High Cost

7.8.2 New Approvals and Expanded Indications


7.9 Solithromycin


8. Carbapenem Market Forecast, 2015-2025

8.1 Carbapenem Market 2013-2014

8.2 Changing Market Share for Carbapenems, 2015-2025

8.3 Carbapenem Market Forecast, 2015-2025

8.4 Trends in the Carbapenem Market

8.4.1 Rising Prevalence of Carbapenemases and β-Lactamases

8.4.2 No New Carbapenems in Late-Stage Trials

8.5 Merrem/Meropenem

8.5.1 Generics Affecting Revenue Worldwide

www.visiongain.com


8.6 Primaxin

8.6.1 Combination Therapy for Lifecycle Management

8.6.2 Historic and Current Revenues


8.7 Invanz


8.8 Doribax

8.8.1 Doribax in HAP and VAP

8.8.2 Lifecycle Management in Japan and the Rest of the World


9. Other Antibiotic Drugs Forecast, 2015-2025 9.1 The Market for Other Classes of Antibacterial Drugs

9.2 Changing Market Share for Fluoroquinolone Antibacterials 2015-2025

9.3 Other Antibacterials: Market Forecast, 2015-2025

9.4 Trends in the Other Classes of Antibacterial Drugs

9.4.1 New Oxazolidinones Will Drive Growth

9.4.2 New Drug Classes to Drive Submarket Growth to 2025

9.5 Zyvox – The Market Leading Antibacterial

9.5.1 MRSA Activity Driving Revenue Growth

9.5.2 Promise in Tuberculosis and Anthrax

9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic

Linezolid?

9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2015-2025

www.visiongain.com

9.6 Cubicin – The Leading Brand for ABSSSIs

9.6.1 Revenue Boosted by Approvals Worldwide

9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?

9.6.3 Sustained Growth through to 2019, Revenue Forecast 2015-2025

9.7 Tygacil – A Tetracycline With Many Approved Indications

9.7.1 Concerns Limiting Revenue Potential

9.7.2 Competition from OtherTherapies Restricts Growth: Revenue Forecast 2015-2025

9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis

9.8.1 Historic and Current Revenue Performance

9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth

9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2015-2025

9.9 Solodyn – A Treatment for Severe Acne

9.9.1 Generic Competition and Lifecycle Management

9.9.2 Limited Potential for Dermatology, Revenue Forecast 2015-2025

9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide

9.10.1 Astellas Ends its Collaboration with Theravance

9.10.2 Limited HAP Label in the US - Revenue Forecast 2015-2025

9.11 Sirturo – A New Option for Multi-Drug Resistant TB

9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast

2015-2025

9.12 Tedizolid – Market Leading Follow-on to Zyvox?

9.12.1 Competition Increasing: Revenue Forecast 2015-2025

9.13 Oritavancin – An Antibiotic With a Novel PK Profile

9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2015-

2025

www.visiongain.com

9.14 Dalbavancin – Competing in a Crowded Indication

9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2015-2025

9.15 Surotomycin –Treatment for C. difficile

9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2015-2025

9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug

9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2015-2025

10. The Leading National Markets, 2015-2025

10.1 US and China Dominate the Global Antibacterial Market, But For Different Reasons

10.2 Above-Average Growth in US: Regional Forecasts, 2015-2025

10.3 China to Slump in Market Share, While Brazil and India Push on

10.4 Incidence of Infection by Country, 2014

10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America

10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets –

High Incidence Rates in the UK, US and Spain

10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – High

Potential in the US

10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads

the Way

10.5 Antibacterial Drug Consumption by Country, 2014

10.5.1 Antibacterial Drug Consumption in the Major National Markets

10.5.2 Antibacterial Drug Consumption in Some Other National Markets

10.6 The Antibacterials Market in the US

10.6.1 Continued Dominance of the US Market

10.7 The European Union Forms Second Largest Regional Market

10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2015-2025

www.visiongain.com

10.7.2 Action to Encourage Antibacterial Drug Development in the EU

10.7.3 Italy Continues to Lead the Way in Antibiotic Use

10.7.4 The French Fascination with Expensive Antibacterial Drugs

10.7.5 Germany – Europe’s Antibiotic Steward

10.7.6 Rising Use of Antibacterials Drugs in the UK

10.7.7 Spanish Antibacterials Market to Expand from 2019 to 2025

10.8 Japan – Still the Third Largest National Market

10.8.1 The Pause Before Growth in the Japanese Market

10.9 Will South Korea Continue Its High Use of Antibiotics?

10.10 BRIC Nation Sales Still Expanding – Market Forecast 2015-2025

10.11 Chinese Antibacterial Market Bloated by Reported Overuse

10.11.1 Developing Antibacterials in China, for China

10.11.2 Governmental Controls Subdue Recent Growth – Market Forecast 2015-2025

10.12 Indian Market to Expand by 50% Over the Forecast Period

10.12.1 Restricting Antibiotic Use in India

10.12.2 Sustained Expansion of the Indian Market, Forecast 2015-2025

10.13 Brazilian Antibacterial Market to Double in Size

10.13.1 Brazilian Market to Be Driven by Drug Resistance

10.14 Russia: TB Prevalence to Stimulate Antibiotic Sales - Forecast 2015-2025

11. Antibacterials R&D Pipeline Review, 2015

11.1 Gram-Positive vs. Gram-Negative

11.2 Pipeline Dominated by Small Molecule Drugs

11.3 Leading Phase III Pipeline Treatment Candidates

11.3.1 Surotomycin – Broad C. difficile Treatment to Reduce Relapse

www.visiongain.com

11.3.2 Tedizolid – More Potent Than Zyvox with Fewer Doses?

11.3.3 Delafloxacin – A Leading pH Activated, Broad Spectrum Fluoroquinolone

11.3.4 Solithromycin – Fluroketolide with Favourable Side Effect Profile

11.3.5 Eravacycline – Treating Gram-Negative cUTIs and cIAIs

11.3.6 Plazomicin – Straight to PIII in Carbapenem Resistant Infections

11.3.7 Cadazolid: Largest PIII C. Difficile Trial

11.4 Leading Phase II Antibacterial Drug Candidates

11.4.1 AZD5847: An Oxazolidinone for TB

11.4.2 Avarofloxacin is Reportedly Still Waiting for a Partner

11.4.3 MK-7655 and Invanz – A Novel β-Lactamase Combination

11.4.4 Omadacycline – Another Phase III-Ready Partnership

11.4.5 Radezolid – Apparently on Melinta’s Back-Burner for Now

11.4.6 AFN-1252: Highly Specific S. Aureus Antibacterial

11.4.7 Sutezolid – Sequella Looking to Combine TB Treatments

11.4.8 Taksta (Fusidic acid) – Cempra’s Second Pipeline Candidate

11.4.9 TD-1792 – A Russian Antibacterial Medicine

11.4.10 Brilacidin – A Novel Peptide Antibacterial Agent

11.4.11POL7080 – Polyphor and Roche in Multi-Million Dollar Deal

11.4.12 BC-3781- Unique Mechanism of Action at 23S?

11.5 Inhaled Antibiotics – Advantages in Lung Infections

11.5.1 Cayston: Competition for Novartis?

11.5.2 ARIKACE – Targeting P. aeruginosa

11.5.3 Aeroquin – Better than Podhaler?

11.5.4 BAYQ3939 – Developments for Cystic Fibrosis

www.visiongain.com

11.5.5 NKTR-061: Targeting Intubated Pneumonia

11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate

11.5.7 AeroVanc Targets MRSA Infections

11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP

11.6 Biologics – Truly Novel Antibacterial Therapeutics

11.6.1 MK-3415A: First Antibacterial mAb to the Market?

11.6.2 KB001A – The Leading Antibody Against P. aeruginosa

11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus

11.6.4 MEDI4893 - Early Stage mAb to S. Aureus

11.7 Other Classes

11.7.1 AZD0914 – Novel DNA Gyrase Inhibitor

11.7.2 MRX-I – Safer Oral Oxazolidinone to Treat MRSA

11.7.3 GSK2140944 – BTI Class of Antibiotics

11.7.4 Carbavance – to Treat CRE

12. Qualitative Analysis of the Antibacterials Industry and Market, 2015

12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting

Antibacterials, their Developers, Producers and Marketers

12.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the

Antibacterial Drug Industry and Market

12.2.1 Social Factors

12.2.2 Technological Developments

12.2.3 Economic Pressures

12.2.4 Political Issues

12.3 Market is Well Established and Demand will Remain Strong

www.visiongain.com

12.4 High Prevalence of Bacterial Infection Worldwide

12.5 Worldwide Demand for Antibacterials

12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic

Fields

12.7 Cutting into a Saturated Market

12.8 Superior Benefit over Generics?

12.9 Resistance – Nature’s Patent Expiry

12.10 Acute Treatment Limits Commercial Potential

12.11 Did Big Pharma Back Away from Antibacterial Drugs?

12.12 Resistance Will Continue to Present New Targets

12.13 First Biologic Antibacterials

12.14 Potential for Smaller Firms to Capitalise

12.15 Developing Preventative Vaccines Rather Than Treatments

12.16 Antibacterial Stewardship Reduces Usage

12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies

12.17.1 Therapeutic Success in European Clinical Trials

12.17.2 Primary End Points in FDA Guidelines

12.18 Reduction in Hospital Infection Rates - Reducing Demand for Antibacterial Drugs

12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives

12.19.1 GAIN act: Post-Development Pull Incentives in the US

12.19.2 ADAPT – Building on the GAIN act

12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU

12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding

12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca

www.visiongain.com

12.19.6 Public Finance Pumping Money into Antibacterial Development

13. Research Interviews from Our Survey 13.1 Dr Bruce R. Donald (Duke University), Dr Amy C. Anderson (University of Connecticut),

and Mr. Pablo Gainza-Cirauqui (Duke University)

13.1.1 OSPREY

13.1.2 OSPREY – Specializes in Accurate Negative Design

13.1.3 Technical Challenges in Predicting Mutations

13.1.4 Success Rate - Top Four Predictions Confirmed in vitro

13.1.5 OSPREY Could Potentially Predict Resistance Mutations to Biologics (mAbs)

13.1.6 Further Work: Optimize Antibody for Highest in vivo Efficacy

13.1.7 Anticipate Mutations – Redesign Drugs to Maximize Effective Lifespan

13.2 Professor Dr Helga Rübsamen-Schaeff, AiCuris GmbH & Co. KG

13.2.1 AiCuris GmbH & Co. KG

13.2.2 Antibacterial Market - Driven by Supportive Frameworks and Initiatives

13.2.3 Surveillance Data of CRO in Germany

13.2.4 CPE in Germany - Regional Spread

13.2.5 AIC499 – to Treat Gram-Negative Infections

13.3 Dr Vu Truong, Founder & CSO, Aridis Pharmaceuticals, United States

13.3.1 Opportunities for Antibacterial Monoclonal Antibodies

13.3.2 Positioning Monoclonal Antibacterials in the Clinic

13.3.3 Differentiating Factor for Biological Antibacterials

13.3.4 Hazard Pitfalls in Clinical Development

13.3.5 Trends in Antibacterial Drug Market – Novel Targets Rewarded

13.3.6 The Commercial Hazard of Acute Therapeutics

www.visiongain.com

13.3.7 Progress from Government Incentives, But More to Come on the Manufacturing Side

13.3.8 Bacteriophages, Potentially Innovative Therapeutics

14. Antibacterial Drugs Market to 2025: Conclusions 14.1 Three Blockbuster Antibacterials in 2014, Leading Brands

14.2 The Leading Branded Antibacterial Drugs in 2025

14.3 Signs of Life in the Antibacterial R&D Pipeline

14.4 Stemming the Tide of Antibacterial Drug Resistance

14.5 The Changing Face of Antibacterial Clinical Development

www.visiongain.com

graphic.designer

Cross-Out

www.visiongain.com Page 104

Antibacterial Drugs: World Industry and Market Prospects 2015-2025

Pfizer also markets an oral form of the drug, Unasyn Oral. The drug's US patent expired in 1999

and its sustained presence in the market has been due to successful lifecycle management

strategies. Revenue has been falling for many years generating revenue of $0.23bn in 2012. In

2013, Pfizer reported revenue of $0.22bn for Unasyn.

5.7.1 Falling Revenues - Forecast 2015-2025

Revenue for Unasyn has been falling since patents covering the drug expired in 1999. This trend

will continue for the coming 10 years with mid-single digit declines in annual revenue, reaching

$0.19bn in 2019 and $0.14bn in 2025 (Table 5.9 and Figure 5.7). Throughout the forecast period of

2014-2025, revenue will fall with a CAGR of -3.5%.

Table 5.9 Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025

2014 2015 2016 2017 2018 2019Unasyn ($bn) 0.21 0.21 0.21 0.21 0.20 0.19

Annual Growth (%) -2.4 3.7 -3.9 -0.2 -3.4 -5.0CAGR (%) -1.8

2020 2021 2022 2023 2024 2025Unasyn ($bn) 0.18 0.16 0.16 0.15 0.14 0.14

Annual Growth (%) -4.8 -9.0 -3.7 -6.9 -6.1 1.5CAGR (%) -4.9

Figure 5.7 Unasyn Forecast: Revenue ($bn), 2015-2025

0.00

0.05

0.10

0.15

0.20

0.25

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Reve

nue

($bn

)

Year

Source: visiongain 2015 – CAGR values for period 2014-2019 and 2019-2025

Source: visiongain 2015




Revenue for Vigamox is expected to peak in 2015 at $0.39bn. However, growth during the year

and beyond will be restrained by increased uptake for Alcon’s other moxifloxacin antibiotic,

Moxeza. Beyond 2020, as well as competition from Moxeza, Vigamox will also compete with

generic competition and subsequent price erosion. Alcon will look to transfer patients onto Moxeza

to replace Vigamox and maintain market share, which will accelerate the decline in revenue for the

former drug. By 2019, revenue will have fallen to $0.31bn (Table 6.11 and Figure 6.7). Revenue is

expected to reach $0.08bn in 2025.

Table 6.11 Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2025

2014 2015 2016 2017 2018 2019Vigamox ($bn) 0.39 0.39 0.37 0.36 0.34 0.31

Annual Growth (%) 1.0 -2.0 -3.0 -4.0 -4.0 -10.0CAGR (%) -4.6

2020 2021 2022 2023 2024 2025Vigamox ($bn) 0.16 0.12 0.10 0.09 0.08 0.08

Annual Growth (%) -50.0 -25.0 -10.0 -10.0 -10.0 -11.5CAGR (%) -21.1

Figure 6.7 Vigamox Forecast: Revenue ($bn), 2015-2025

0.00

0.10

0.20

0.30

0.40

0.50

0.60

0.70

0.80

0.90

1.00

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Reve

nue

($bn

)

Year





antibiotics with 13.9 DDD per 1000 inhabitants per day. However, consumption per capita has

risen by 10% over the past decade and visiongain anticipates a greater demand for antibiotics over

the coming 10 years. This increase in demand will be driven by an increase in the average age of

the population and subsequent rise in incidence of urinary tract infections and pneumonia.

Table 10.14 German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025

2014 2015 2016 2017 2018 2019Germany ($bn) 1.06 1.06 1.08 1.10 1.12 1.15

Annual Growth (%) -1.0 0.5 1.2 2.5 1.5 2.5CAGR (%) 1.6

2020 2021 2022 2023 2024 2025Germany ($bn) 1.17 1.19 1.22 1.25 1.29 1.32

Annual Growth (%) 2.0 2.0 2.5 2.5 2.9 2.4CAGR (%) 2.4

Figure 10.9 German Antibacterial Drugs Market: Revenue Forecast ($bn), 2015-2025

10.7.6 Rising Use of Antibacterials Drugs in the UK

Though some countries have reported declining prescribing rates for antibiotics in recent years, in

the UK it has risen. Over the last decade, antibacterial consumption within the UK has increased

0.00

0.20

0.40

0.60

0.80

1.00

1.20

1.40

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Mar

ket s

ize

($bn

)

Year



Antibacterial Drugs: World Industry and Market Prospects 2015 2025

Business

Transcript of Antibacterial Drugs: World Industry and Market Prospects 2015 2025